SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

02.07.25 15:24 Uhr

Werte in diesem Artikel

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws.

DJS Law Group

Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.

CASE DETAILS:  The complaint alleges that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having strong growth potential due to a lack of hindrances to broader use.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit---contact-the-djs-law-group-before-the-final-deadline---srpt-302496453.html

SOURCE DJS Law Group LLP

In eigener Sache

Übrigens: Sarepta Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Sarepta Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sarepta Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sarepta Therapeutics Inc.

Wer­bung

Analysen zu Sarepta Therapeutics Inc.

DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
22.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
20.05.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
23.01.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
28.10.2014Sarepta Therapeutics NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics ReduceSunTrust Robinson Humphrey, Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sarepta Therapeutics Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen